Q2 revenue rises 40%, margin expands, and FY28 capacity targets are set

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹188.50

prior close

₹186.41

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.2%-2.0% vs sector

On the reaction day the stock moved 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.1

15m

-1.2

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2pendingpending-0.2-2.0

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 40% year on year to INR795 crore, while EBITDA rose nearly 80% to INR115 crore and margin improved to 14.4%. PAT jumped 117% to INR65 crore. H1 revenue was INR1,551 crore, up 39%. Management expects FY27 revenue growth above 25% and a 14-15% EBITDA margin. Ibuprofen capacity of 18,000 MT and the new CDMO plant are targeted for FY28, with fuller benefits in FY28-FY29.

Likely market impact

Strong results may support the share price, but FY28 project execution, capacity ramp-up and higher working-capital and finance costs are key risks.